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A programmable synthetic lineage-control
network that differentiates human IPSCs into
glucose-sensitive insulin-secreting beta-like cells
Pratik Saxena1, Boon Chin Heng1,w, Peng Bai1, Marc Folcher1, Henryk Zulewski1,2,w & Martin Fussenegger1,3
Synthetic biology has advanced the design of standardized transcription control devices that
programme cellular behaviour. By coupling synthetic signalling cascade- and transcription
factor-based gene switches with reverse and differential sensitivity to the licensed food
additive vanillic acid, we designed a synthetic lineage-control network combining vanillic
acid-triggered mutually exclusive expression switches for the transcription factors Ngn3
(neurogenin 3; OFF-ON-OFF) and Pdx1 (pancreatic and duodenal homeobox 1; ON-OFF-ON)
with the concomitant induction of MafA (V-maf musculoaponeurotic ﬁbrosarcoma oncogene
homologue A; OFF-ON). This designer network consisting of different network topologies
orchestrating the timely control of transgenic and genomic Ngn3, Pdx1 and MafA variants is
able to programme human induced pluripotent stem cells (hIPSCs)-derived pancreatic
progenitor cells into glucose-sensitive insulin-secreting beta-like cells, whose glucose-
stimulated insulin-release dynamics are comparable to human pancreatic islets. Synthetic
lineage-control networks may provide the missing link to genetically programme somatic cells
into autologous cell phenotypes for regenerative medicine.
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C
ell-fate decisions during development are regulated
by various mechanisms, including morphogen gradients,
regulated activation and silencing of key transcription
factors, microRNAs, epigenetic modiﬁcation and lateral
inhibition. The latter implies that the decision of one cell to
adopt a speciﬁc phenotype is associated with the inhibition of
neighbouring cells to enter the same developmental path. In
mammals, insights into the role of key transcription factors that
control development of highly specialized organs like the
pancreas were derived from experiments in mice, especially
various genetically modiﬁed animals1–4. Normal development of
the pancreas requires the activation of pancreatic duodenal
homeobox protein (Pdx1) in pre-patterned cells of the endoderm.
Inactivating mutations of Pdx1 are associated with pancreas
agenesis in mouse and humans5,6. A similar cell fate decision
occurs later with the activation of Ngn3 that is required for
the development of all endocrine cells in the pancreas7. Absence
of Ngn3 is associated with the loss of pancreatic endocrine cells,
whereas the activation of Ngn3 not only allows the differentiation
of endocrine cells but also induces lateral inhibition of
neighbouring cells—via Delta-Notch pathway—to enter the
same pancreatic endocrine cell fate8. This Ngn3-mediated
cell-switch occurs at a speciﬁc time point and for a short
period of time in mice9. Thereafter, it is silenced and becomes
almost undetectable in postnatal pancreatic islets. Conversely,
Pdx1-positive Ngn3-positive cells reduce Pdx1 expression, as
Ngn3-positive cells are Pdx1 negative10. They re-express Pdx1,
however, as they go on their path towards glucose-sensitive
insulin-secreting cells with parallel induction of MafA that is
required for proper differentiation and maturation of pancreatic
beta cells11. Data supporting these expression dynamics are
derived from mice experiments1,11,12. A synthetic gene-switch
governing cell fate decision in human induced pluripotent
stem cells (hIPSCs) could facilitate the differentiation of
glucose-sensitive insulin-secreting cells.
In recent years, synthetic biology has signiﬁcantly advanced the
rational design of synthetic gene networks that can interface with
host metabolism, correct physiological disturbances13 and
provide treatment strategies for a variety of metabolic disorders,
including gouty arthritis14, obesity15 and type-2 diabetes16.
Currently, synthetic biology principles may provide the
componentry and gene network topologies for the assembly of
synthetic lineage-control networks that can programme cell-fate
decisions and provide targeted differentiation of stem cells into
terminally differentiated somatic cells. Synthetic lineage-control
networks may therefore provide the missing link between human
pluripotent stem cells17 and their true impact on regenerative
medicine18–20. The use of autologous stem cells in regenerative
medicine holds great promise for curing many diseases, including
type-1 diabetes mellitus (T1DM), which is characterized by the
autoimmune destruction of insulin-producing pancreatic beta
cells, thus making patients dependent on exogenous insulin to
control their blood glucose21,22. Although insulin therapy has
changed the prospects and survival of T1DM patients, these
patients still suffer from diabetic complications arising from the
lack of physiological insulin secretion and excessive glucose
levels23. The replacement of the pancreatic beta cells either by
pancreas transplantation or by transplantation of pancreatic islets
has been shown to normalize blood glucose and even improve
existing complications of diabetes24. However, insulin
independence 5 years after islet transplantation can only be
achieved in up to 55% of the patients even when using the
latest generation of immune suppression strategies25,26.
Transplantation of human islets or the entire pancreas
has allowed T1DM patients to become somewhat insulin
independent, which provides a proof-of-concept for beta-cell
replacement therapies27,28. However, because of the shortage
of donor pancreases and islets, as well as the signiﬁcant
risk associated with transplantation and life-long immuno-
suppression, the rational differentiation of stem cells into
functional beta-cells remains an attractive alternative29,30.
Nevertheless, a deﬁnitive cure for T1DM should address both
the beta-cell deﬁcit and the autoimmune response to cells that
express insulin. Any beta-cell mimetic should be able to store
large amounts of insulin and secrete it on demand, as in response
to glucose stimulation29,31. The most effective protocols for the
in vitro generation of bonaﬁde insulin-secreting beta-like cells
that are suitable for transplantation have been the result of
sophisticated trial-and-error studies elaborating timely addition
of complex growth factor and small-molecule compound
cocktails to human pancreatic progenitor cells32–34. The
differentiation of pancreatic progenitor cells to beta-like cells is
the most challenging part as current protocols provide
inconsistent results and limited success in programming
pancreatic progenitor cells into glucose-sensitive insulin-
secreting beta-like cells35–37. One of the reasons for these
observations could be the heterogeneity in endocrine
differentiation and maturation towards a beta cell phenotype.
Figure 1 | Design of a vanillic acid-responsive positive band-pass ﬁlter providing an OFF-ON-OFF expression proﬁle. (a) Vanillic acid-inducible
transgene expression. The constitutively expressed vanillic acid-sensitive olfactory G protein-coupled receptor MOR9-1 (pCI-MOR9-1; PhCMV-MOR9-1-pA)
senses extracellular vanillic acid levels and triggers G protein (Gs)-mediated activation of the membrane-bound adenylyl cyclase (AC) that converts ATP
into cyclic AMP (cAMP). The resulting intracellular cAMP surge activates PKA (protein kinase A), whose catalytic subunits translocate into the nucleus to
phosphorylate cAMP response element-binding protein 1 (CREB1). Activated CREB1 binds to synthetic promoters (PCRE) containing cAMP-response
elements (CRE) and induces PCRE-driven expression of human placental secreted alkaline phosphatase (SEAP; pCK53, PCRE-SEAP-pA). Co-transfection of
pCI-MOR9-1 and pCK53 into human mesenchymal stem cells (hMSC-TERT) grown for 48 h in the presence of increasing vanillic acid concentrations
results in a dose-inducible SEAP expression proﬁle. (b) Vanillic acid-repressible transgene expression. The constitutively expressed, vanillic acid-dependent
transactivator VanA1 (pMG250, PSV40-VanA1-pA, VanA1, VanR-VP16) binds and activates the chimeric promoter P1VanO2 (pMG252, P1VanO2-SEAP-pA) in
the absence of vanillic acid. In the presence of increasing vanillic acid concentrations, VanA1 is released from P1VanO2, and transgene expression is shut
down. Co-transfection of pMG250 and pMG252 into hMSC-TERTgrown for 48 h in the presence of increasing vanillic acid concentrations results in a dose-
repressible SEAP expression proﬁle. (c) Positive band-pass expression ﬁlter. Serial interconnection of the synthetic vanillic acid-inducible signalling cascade
(a) with the vanillic acid-repressible transcription factor-based gene switch (b) by PCRE-mediated expression of VanA1 (pSP1, PCRE-VanA1-pA) results in a
two-level feed-forward cascade. Owing to the opposing responsiveness and differential sensitivity to vanillic acid, this synthetic gene network programmes
SEAP expression with a positive band-pass ﬁlter proﬁle (OFF-ON-OFF) as vanillic acid levels are increased. Medium vanillic acid levels activate MOR9-1,
which induces PCRE-driven VanA1 expression. VanA1 remains active and triggers P1VanO2-mediated SEAP expression in feed-forward manner, which
increases to maximum levels. At high vanillic acid concentrations, MOR9-1 maintains PCRE-driven VanA1 expression, but the transactivator dissociates from
P1VanO2, which shuts SEAP expression down. Co-transfection of pCI-MOR9-1, pSP1 and pMG252 into hMSC-TERT grown for 48 h in the presence of
increasing vanillic acid concentrations programmes SEAP expression with a positive band-pass proﬁle (OFF-ON-OFF). Data are the means±s.d. of
triplicate experiments (n¼ 9).
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Here we show that a synthetic lineage-control network
programming the dynamic expression of the transcription
factors Ngn3, Pdx1 and MafA enables the differentiation of
hIPSC-derived pancreatic progenitor cells to glucose-sensitive
insulin-secreting beta-like cells (Supplementary Fig. 1).
Results
Vanillic acid-programmable positive band-pass ﬁlter. The dif-
ferentiation pathway from pancreatic progenitor cells to
glucose-sensitive insulin-secreting pancreatic beta-cells combines
the transient mutually exclusive expression switches of Ngn3
(OFF-ON-OFF) and Pdx1 (ON-OFF-ON) with the concomitant
induction of MafA (OFF-ON) expression10,11. Since independent
control of the pancreatic transcription factors Ngn3, Pdx1 and
MafA by different antibiotic transgene control systems responsive
to tetracycline, erythromycin and pristinamycin did not result in
the desired differential control dynamics (Supplementary Fig. 2),
we have designed a vanillic acid-programmable synthetic lineage-
control network that programmes hIPSC-derived pancreatic
progenitor cells to speciﬁcally differentiate into glucose-sensitive
insulin-secreting beta-like cells in a seamless and self-sufﬁcient
manner. The timely coordination of mutually exclusive Ngn3
and Pdx1 expression with MafA induction requires the
trigger-controlled execution of a complex genetic programme
that orchestrates two overlapping antagonistic band-pass ﬁlter
expression proﬁles (OFF-ON-OFF and ON-OFF-ON), a positive
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band-pass ﬁlter for Ngn3 (OFF-ON-OFF) and a negative
band-pass ﬁlter, also known as band-stop ﬁlter, for Pdx1
(ON-OFF-ON), the ramp-up expression phase of which is
linked to a graded induction of MafA (OFF-ON).
The core of the synthetic lineage-control network consists of
two transgene control devices that are sensitive to the food
component and licensed food additive vanillic acid. These devices
are a synthetic vanillic acid-inducible (ON-type) signalling
cascade that is gradually induced by increasing the vanillic acid
concentration and a vanillic acid-repressible (OFF-type) gene
switch that is repressed in a vanillic acid dose-dependent manner
(Fig. 1a,b). The designer cascade consists of the vanillic
acid-sensitive mammalian olfactory receptor MOR9-1, which
sequentially activates the G protein Sa (GSa) and adenylyl cyclase
to produce a cyclic AMP (cAMP) second messenger surge38 that
is rewired via the cAMP-responsive protein kinase A-mediated
phospho-activation of the cAMP-response element-binding
protein 1 (CREB1) to the induction of synthetic promoters
(PCRE) containing CREB1-speciﬁc cAMP response elements
(CRE; Fig. 1a). The co-transfection of pCI-MOR9-1
(PhCMV-MOR9-1-pASV40) and pCK53 (PCRE-SEAP-pASV40) into
human mesenchymal stem cells (hMSC-TERT) conﬁrmed the
vanillic acid-adjustable secreted alkaline phosphatase (SEAP)
induction of the designer cascade (410 nM vanillic acid; Fig. 1a).
The vanillic acid-repressible gene switch consists of the vanillic
acid-dependent transactivator (VanA1), which binds and activates
vanillic acid-responsive promoters (for example, P1VanO2) at low
and medium vanillic acid levels (o2 mM). At high vanillic acid
concentrations (42 mM), VanA1 dissociates from P1VanO2,
which results in the dose-dependent repression of transgene
expression39 (Fig. 1b). The co-transfection of pMG250
(PSV40-VanA1-pASV40) and pMG252 (P1VanO2-SEAP-pASV40)
into hMSC-TERT corroborated the ﬁne-tuning of the vanillic
acid-repressible SEAP expression (Fig. 1b).
The opposing responsiveness and differential sensitivity of the
control devices to vanillic acid are essential to programme
band-pass ﬁlter expression proﬁles. Upon daisy-chaining the
designer cascade (pCI-MOR9-1; PhCMV-MOR9-1-pASV40; pSP1,
PCRE-VanA1-pASV40) and the gene switch (pSP1, PCRE-VanA1-
pASV40; pMG252, P1VanO2-SEAP-pASV40) in the same cell, the
network executes a band-pass ﬁlter SEAP expression proﬁle when
exposed to increasing concentrations of vanillic acid (Fig. 1c).
Medium vanillic acid levels (10 nM to 2 mM) activate MOR9-1,
which induces PCRE-driven VanA1 expression. VanA1 remains
active within this concentration range and, in a feed-forward
ampliﬁer manner, triggers P1VanO2-mediated SEAP expression,
which gradually increases to maximum levels (Fig. 1c). At high
vanillic acid concentrations (2 mM to 400 mM), MOR9-1 main-
tains PCRE-driven VanA1 expression, but the transactivator is
inactivated and dissociates from P1VanO2, which results in the
gradual shutdown of SEAP expression (Fig. 1c).
Vanillic acid-programmable lineage-control network. For the
design of the vanillic acid-programmable synthetic lineage-
control network, constitutive MOR9-1 expression and PCRE-
driven VanA1 expression were combined with pSP12
(pASV40-Ngn3cm’P3VanO2-mFT-miR30Pdx1g-shRNA-pASV40) for
endocrine speciﬁcation and pSP17 (PCREm-Pdx1cm-2A-MafAcm-
pASV40) for maturation of developing beta-cells (Fig. 2a,b). The
pSP12-encoded expression unit enables the VanA1-controlled
induction of the optimized bidirectional vanillic acid-responsive
promoter (P3VanO2) that drives expression of a codon-modiﬁed
Ngn3cm, the nucleic acid sequence of which is distinct from its
genomic counterpart (Ngn3g) to allow for quantitative reverse
transcription–PCR (qRT–PCR)-based discrimination. In the
opposite direction, P3VanO2 transcribes miR30Pdx1g-shRNA, which
exclusively targets genomic Pdx1 (Pdx1g) transcripts for RNA
interference-based destruction and is linked to the production of
a blue-to-red medium ﬂuorescent timer40 (mFT) for precise
visualization of the unit’s expression dynamics in situ. pSP17
contains a dicistronic expression unit in which the modiﬁed high-
tightness and lower-sensitivity PCREm promoter (see below) drives
co-cistronic expression of Pdx1cm and MafAcm, which are codon-
modiﬁed versions producing native transcription factors that
speciﬁcally differ from their genomic counterparts (Pdx1g,MafAg)
in their nucleic acid sequence. After individual validation of the
vanillic acid-controlled expression and functionality of all
network components (Supplementary Figs 2–9), the lineage-
control network was ready to be transfected into hIPSC-derived
pancreatic progenitor cells. These cells are characterized by high
expression of Pdx1g and Nkx6.1 levels and the absence of Ngn3g
and MafAg production32–34 (day 0: Supplementary Figs 10–16).
Following the co-transfection of pCI-MOR9-1 (PhCMV-
MOR9-1-pASV40), pSP1 (PCRE-VanA1-pASV40), pSP12 (pASV40-
Ngn3cm’P3VanO2-mFT-miR30Pdx1g-shRNA-pASV40) and pSP17
(PCREm-Pdx1cm-2A-MafAcm-pASV40) into hIPSC-derived pan-
creatic progenitor cells, the synthetic lineage-control network
should override random endogenous differentiation activities and
execute the pancreatic beta-cell-speciﬁc differentiation pro-
gramme in a vanillic acid remote-controlled manner. To conﬁrm
that the lineage-control network operates as programmed,
we cultivated network-containing and pEGFP-N1-transfected
(negative-control) cells for 4 days at medium (2 mM) and then 7
days at high (400 mM) vanillic acid concentrations and proﬁled
the differential expression dynamics of all of the network
components and their genomic counterparts as well as the
interrelated transcription factors and hormones in both whole
populations and individual cells at days 0, 4, 11 and 14 (Figs 2
and 3 and Supplementary Figs 11–17).
Validation of the lineage-control dynamics. The aforemen-
tioned detailed analysis demonstrated that the following three
expression protocols were simultaneously executed:
Positive band-pass Ngn3 expression proﬁle (OFF-ON-OFF):
medium vanillic acid concentrations trigger the MOR9-1-based
designer cascade and induce PCRE-driven VanA1 expression.
Because VanA1 remains fully active at medium vanillic acid levels,
it transactivates the bidirectional promoter P3VanO2 and induces
Ngn3cm expression (Fig. 3a). Ngn3cm triggers the transcription of
Ngn3g from its genomic promoter, which initiates a positive-
feedback loop8, resulting in high-level expression of Ngn3g
(OFF-ON; Fig. 3a–d and Supplementary Fig. 17) as well as its
target genes Pax4 (paired box gene 4) and the notch-signalling
components Hes1 (hairy and enhancer of split-1) and Dll1
(delta-like 1), which manage lateral inhibition (a developmental
pathway suppressing similar differentiation of neighbouring
cells8,41; day 4; Supplementary Fig. 17). NeuroD1 (neurogenic
differentiation factor 1) expression levels in network-transfected
cells remained identical to randomly differentiating cells (days 4;
Supplementary Fig. 17). After switching the cells to high vanillic
acid concentrations, VanA1 was released from P3VanO2 and
Ngn3cm, and Ngn3g expression halted, which resulted in an
overall decrease of this transcription factor (ON-OFF; day 11;
Fig. 3a,b).
Negative band-pass/band-stop ﬁlter Pdx1 expression proﬁle
(ON-OFF-ON): Following the MOR9-1-mediated activation
of PCRE-driven VanA1 expression at medium vanillic acid
concentrations, VanA1 co-induces the P3VanO2-driven
expression of Ngn3cm and miR30Pdx1g-shRNA. As Ngn3cm
and miR30Pdx1g-shRNA levels increase, miR30Pdx1g-shRNA
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programmes the exclusive destruction of genomic Pdx1 (Pdx1g)
transcripts, which results in a reduction of Pdx1g levels (ON-OFF;
Fig. 3b). Because PCREm-driven Pdx1cm-2A-MafAcm transcription
is silent at medium vanillic acid concentrations, the overall
cellular Pdx1cm/g content remains low (day 4; Fig. 3a–c). At high
vanillic acid concentrations, where VanA1 is inactivated and
P3VanO2-driven miR30Pdx1g-shRNA expression is shut down,
PCREm-mediated Pdx1cm expression ramps up and initiates a
positive-feedback loop by inducing Pdx1g42 as well MafAg43 (see
below) from their genomic promoters, which results in sustained
high-level Pdx1g and MafAg expression (OFF-ON; day 11;
Fig. 3b,e–g). Importantly, Pdx1cm levels are not affected by
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Figure 2 | Synthetic lineage-control network programming differential expression dynamics of pancreatic transcription factors. (a) Schematic of
the synthetic lineage-control network. The constitutively expressed, vanillic acid-sensitive olfactory G protein-coupled receptor MOR9-1 (pCI-MOR9-1;
PhCMV-MOR9-1-pA) senses extracellular vanillic acid levels and triggers a synthetic signalling cascade, inducing PCRE-driven expression of the transcription
factor VanA1 (pSP1, PCRE-VanA1-pA). At medium vanillic acid concentrations (purple arrows), VanA1 binds and activates the bidirectional vanillic
acid-responsive promoter P3VanO2 (pSP12, pA-Ngn3cm’P3VanO2-mFT-miR30Pdx1g-shRNA-pA), which drives the induction of codon-modiﬁed Neurogenin 3
(Ngn3cm) as well as the coexpression of both the blue-to-red medium ﬂuorescent timer (mFT) for precise visualization of the unit’s expression dynamics
and miR30pdx1g-shRNA (a small hairpin RNA programming the exclusive destruction of genomic pancreatic and duodenal homeobox 1 (Pdx1g) transcripts).
Consequently, Ngn3cm levels switch from low to high (OFF-to-ON), and Pdx1g levels toggle from high to low (ON-to-OFF). In addition, Ngn3cm triggers the
transcription of Ngn3g from its genomic promoter, which initiates a positive-feedback loop. At high vanillic acid levels (orange arrows), VanA1 is inactivated,
and both Ngn3cm and miR30pdx1g-shRNA are shut down. At the same time, the MOR9-1-driven signalling cascade induces the modiﬁed high-tightness and
lower-sensitivity PCREm promoter that drives the co-cistronic expression of the codon-modiﬁed variants of Pdx1 (Pdx1cm) and V-maf musculoaponeurotic
ﬁbrosarcoma oncogene homologue A (MafAcm; pSP17, PCREm-Pdx1cm-2A-MafAcm-pA). Consequently, Pdx1cm and MafAcm become fully induced.
As Pdx1cm expression ramps up, it initiates a positive-feedback loop by inducing the genomic counterparts Pdx1g and MafAg. Importantly, Pdx1cm levels
are not affected by miR30Pdx1g-shRNA because the latter is speciﬁc for genomic Pdx1g transcripts and because the positive feedback loop-mediated
ampliﬁcation of Pdx1g expression becomes active only after the shutdown of miR30Pdx1g-shRNA. Overall, the synthetic lineage-control network provides
vanillic acid-programmable, transient, mutually exclusive expression switches for Ngn3 (OFF-ON-OFF) and Pdx1 (ON-OFF-ON) as well as the concomitant
induction of MafA (OFF-ON) expression, which can be followed in real time (Supplementary Movies 1 and 2). (b) Schematic illustrating the individual
differentiation steps from human IPSCs towards beta-like cells. The colours match the cell phenotypes reached during the individual differentiation stages
programmed by the lineage-control network shown in a.
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Figure 3 | Dynamics of the lineage-control network. (a,b) Quantitative RT–PCR-based expression proﬁling of the pancreatic transcription factors
Ngn3cm/g, Pdx1cm/g and MafAcm/g in hIPSC-derived pancreatic progenitor cells containing the synthetic lineage-control network at days 4 and 11. Data are
the means±s.d. of triplicate experiments (n¼ 9). (c–g) Immunocytochemistry of pancreatic transcription factors Ngn3cm/g, Pdx1cm/g and MafAcm/g in
hIPSC-derived pancreatic progenitor cells containing the synthetic lineage-control network at days 4 and 11. hIPSC-derived pancreatic progenitor cells
were co-transfected with the lineage-control vectors pCI-MOR9-1 (PhCMV-MOR9-1-pA), pSP1 (PCRE-VanA1-pA), pSP12 (pA-Ngn3cm’P3VanO2-
mFT-miR30Pdx1g-shRNA-pA) and pSP17 (PCREm-Pdx1cm-2A-MafAcm) and immunocytochemically stained for (c) VanA1 and Pdx1 (day 4), (d) VanA1 and
Ngn3 (day 4), (e) VanA1 and Pdx1 (day 11), (f) MafA and Pdx1 (day 11) as well as (g) VanA1 and insulin (C-peptide) (day 11). The cells staining positive for
VanA1 are containing the lineage-control network. DAPI, 4
0,6-diamidino-2-phenylindole. Scale bar, 100mm.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms11247
6 NATURE COMMUNICATIONS | 7:11247 |DOI: 10.1038/ncomms11247 | www.nature.com/naturecommunications
miR30Pdx1g-shRNA, as it is speciﬁc for genomic Pdx1g transcripts,
and the positive-feedback loop-mediated ampliﬁcation of
Pdx1g expression becomes active only after the shutdown of
miR30Pdx1g-shRNA (Supplementary Fig. 18). The transition
between miR30Pdx1g-shRNA-mediated knockdown and PCREm-
driven Pdx1cm ramp-up requires a time delay in the production of
both components that results from the combination of the higher
vanillic acid sensitivity and induction kinetics of PCRE compared
with PCREm (Supplementary Fig. 7; see below) and the fact that
miR30Pdx1g-shRNA is driven by a two-level cascade (PCRE
inducing VanA1; VanA1 activating P3VanO2), which then leads
to feed-forward loop-type signal ampliﬁcation and increased
expression kinetics of miR30Pdx1g-shRNA compared with Pdx1cm
(Supplementary Fig. 18). The time delay and correlating
expression dynamics of Ngn3cm, miR30Pdx1g-shRNA and Pdx1cm
can be visualized in real time because miR30Pdx1g-shRNA is linked
to the expression of the blue-to-red mFT 40 and because the
PCREm-mediated dicistronic expression of Pdx1cm-2A-MafAcm can
be linked to an isogenic PCREm-driven enhanced yellow
ﬂuorescent protein (EYFP) expression plug-in (pSP24; PCREm-
EYFP-pASV40). During the co-induction of Ngn3cm and
miR30Pdx1g-shRNA as well as miR30Pdx1g-shRNA-mediated Pdx1g
knockdown at medium vanillic acid concentrations, the cells ﬁrst
ﬂuoresce in blue and then simultaneously in blue and red as the
mFT matures (Supplementary Movie 1). After switching the
culture to high vanillic acid and repressing P3VanO2-driven
Ngn3cm, miR30Pdx1g-shRNA and mFT de novo synthesis, all cells
contain fully matured mFT and exclusively ﬂuoresce in red
(Supplementary Movie 2). After the transition to PCREm-mediated
Pdx1cm and MafAcm production, the cells express EYFP and
ﬂuoresce in yellow (Supplementary Movie 2).
MafA induction proﬁle (OFF-ON): Because PCREm has been
optimized for tightness and decreased vanillic acid sensitivity44,
MafAcm is repressed at medium vanillic acid concentrations, as is
required for the early phase of the differentiation process45 when
Ngn3cm is induced and Pdx1g is repressed (day 4; Fig. 3a,b). At
high vanillic acid levels, MafAcm is co-cistronically expressed with
Pdx1cm by PCREm; therefore, the time-delayed production onset of
MafAcm matches that of Pdx1cm (OFF-ON; Fig. 3a,b). MafAcm
triggers a positive-feedback loop by activating Pdx1g expression46
from its genomic promoter, which results in sustained high-level
MafAg and Pdx1g expression that compensates for the initial
lower-level induction by PCREm (day 11; Fig. 3a,b,e–g).
Validation of beta-like cells programmed by the network. To
validate the beta-like cells genetically programmed from
hIPSC-derived pancreatic progenitor cells using the synthetic
lineage-control network, we compared their phenotype to cells
produced using the growth-factor/chemical-based differentiation
technique (Supplementary Figs 1 and 19) as well as to human
pancreatic islets. Following individual execution of the two dif-
ferentiation programmes (synthetic lineage-control network and
growth-factor/chemical-based protocol; day 11), insulin-secreting
beta-like cells were isolated by ﬂow cytometry and proﬁled by
quantitative RT–PCR for the expression levels of key beta-cell-
speciﬁc markers relative to human pancreatic islets32–34,47–49
(Fig. 4).
Compared with human pancreatic islets, the beta-like cells
produced by the synthetic lineage-control programme showed
similar levels of (i) the transcription factors MafA, NeuroD, Pax4
and Pdx1, whereas NeuroD, Pax4 and Pdx1 were expressed at
lower levels in beta-like cells produced by the growth-factor/
chemical-based differentiation technique (Fig. 4a). (ii) Likewise,
the glucose-processing factors such as Gck (glucokinase) and
G6pc2 (glucose-6-phosphatase 2) as well as the insulin-processing
factor Pcsk1 (prohormone convertase 1) were expressed at higher
levels in beta-like cells produced using the lineage-control
network compared with those resulting from the growth-factor/
chemical-based differentiation technique (Fig. 4b). (iii) The
expression levels of channels essential for the secretion of insulin
were comparable between beta-like cells produced by either
differentiation strategy (Fig. 4c). (iv) Insulin expression was much
higher in lineage-controlled than growth-factor/chemical-differ-
entiated beta-like cells. Yet, insulin expression of lineage-
controlled beta-like cells was not quite reaching the levels of
human pancreatic islets (Fig. 4d). The expression of somatostatin
and glucagon was substantially lower in lineage-controlled than
growth-factor/chemical-differentiated beta-like cells (Fig. 4d).
(v) Markers speciﬁc for immature beta-cells such as Ck19
(Cytokeratin 19), Irx2 (Iroquois homeobox 2) and Acox2
(Acyl-CoA oxidase 2) were expressed at lower levels, whereas
markers speciﬁc for mature beta-cells such as FoxA1 (Forkhead
box A1 (ref. 50) and Gcgr (Glucagon receptor) were expressed at a
higher levels in lineage- than growth-factor/chemical-controlled
beta-like cells (Fig. 4e). (vi) Flow-cytometric analysis of insulin
(C-peptide), glucagon and somatostatin revealed that most
lineage-controlled beta-like cells stained positive for the lineage-
control network component VanA1 as well as insulin (C-peptide),
whereas only very few VanA1-containing cells co-stained for
glucagon and somatostatin (Fig. 5a and Supplementary Fig. 20a).
These data conﬁrmed that over 75% of the hIPSC-derived
pancreatic progenitors transfected with the synthetic lineage-
control network indeed differentiated into glucose-sensitive
insulin-secreting beta-like cells (Fig. 5a and Supplementary
Fig. 20a). By contrast, the growth-factor/chemical-based differ-
entiation technique only produced 26% of insulin-secreting
beta-like cells (Supplementary Fig. 20b,c). (vii) In addition, the
intracellular insulin (C-peptide) content was substantially higher
in lineage-controlled beta-like cells compared with those resulting
from the growth-factor/chemical-based differentiation technique,
albeit lower than in human pancreatic islets (Fig. 5b). (viii) Most
importantly, the dynamics of glucose-stimulated insulin release of
lineage-controlled beta-like cells was similar to that of human
pancreatic islets, whereas beta-like cells differentiated by the
growth factor/chemical-based differentiation technique showed
poor glucose-stimulated insulin release (Fig. 5c). In addition, the
lineage-controlled beta-like cells maintained glucose-stimulated
insulin release during extended culture periods of up to 4 weeks
(Fig. 5d).
Overall, all of these characteristics corroborate our ﬁnding that
the synthetic lineage-control network is able to programme the
cell fate of hIPSC-derived pancreatic progenitor cells and
speciﬁcally differentiate them into glucose-sensitive insulin-
secreting pancreatic beta-like cells. Indeed, electron micrographs
of these lineage-controlled beta-like cells show the typical
insulin-storage vesicles that are found in mature pancreatic beta
cells (Fig. 5e).
Discussion
Multicellular organisms, including humans, consist of a highly
structured assembly of a multitude of specialized cell phenotypes
that originate from the same zygote and have traversed
a preprogrammed multifactorial developmental plan that
orchestrates sequential differentiation steps with high precision
in space and time19,51. Because of the complexity of terminally
differentiated cells, the function of damaged tissues can for most
medical indications only be restored via the transplantation of
donor material, which is in chronically short supply52.
Despite signiﬁcant progress in regenerative medicine and the
availability of stem cells, the design of protocols that replicate
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natural differentiation programmes and provide fully functional
cell mimetics remains challenging29,53. For example, efforts to
generate beta-cells from human embryonic stem cells (hESCs)
have led to reliable protocols involving the sequential
administration of growth factors (activin A, bone
morphogenetic protein 4 (BMP-4), basic ﬁbroblast growth
factor (bFGF), FGF-10, Noggin, vascular endothelial growth
factor (VEGF) and Wnt3A) and small-molecule compounds
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(cyclopamine, forskolin, indolactam V, IDE1, IDE2,
nicotinamide, retinoic acid, SB 431542 and g-secretase
inhibitor) that modulate differentiation-speciﬁc signalling
pathways31,54,55. In vitro differentiation of hESC-derived
pancreatic progenitor cells into beta-like cells is more
challenging and has been achieved recently by a complex media
formulation with chemicals and growth factors32–34.
hIPSCs have become a promising alternative to hESCs;
however, their use remains restricted in many countries56. Most
hIPSCs used for directed differentiation studies were derived
from a juvenescent cell source that is expected to show a higher
degree of differentiation potential compared with older donors
that typically have a higher need for medical interventions37,57,58.
We previously succeeded in producing mRNA-reprogrammed
hIPSCs from adipose tissue-derived mesenchymal stem cells of a
50-year-old donor, demonstrating that the reprogramming of
cells from a donor of advanced age is possible in principle59.
Recent studies applying similar hESC-based differentiation
protocols to hIPSCs have produced cells that release insulin in
response to high glucose32–34. This observation suggests that
functional beta-like cells can eventually be derived from
hIPSCs32,33. In our hands, the growth-factor/chemical-based
technique for differentiating human IPSCs resulted in beta-like
cells with poor glucose responsiveness. Recent studies have
revealed signiﬁcant variability in the lineage speciﬁcation
propensity of different hIPSC lines35,60 and substantial
differences in the expression proﬁles of key transcription factors
in hIPSC-derived beta-like cells33. Therefore, the growth-factor/
chemical-based protocols may require further optimization and
need to be customized for speciﬁc hIPSC lines35. Synthetic
lineage-control networks providing precise dynamic control of
transcription factor expression may overcome the challenges
associated with the programming of beta-like cells from different
hIPSC lines.
Rather than exposing hIPSCs to a reﬁned compound cocktail
that triggers the desired differentiation in a fraction of the stem
cell population, we chose to design a synthetic lineage-control
network to enable single input-programmable differentiation of
hIPSC-derived pancreatic progenitor cells into glucose-sensitive
insulin-secreting beta-like cells. In contrast with the use of
growth-factor/chemical-based cocktails, synthetic lineage-control
networks are expected to (i) be more economical because of
in situ production of the required transcription factors, (ii) enable
simultaneous control of ectopic and chromosomally encoded
transcription factor variants, (iii) tap into endogenous pathways
and not be limited to cell-surface input, (iv) display improved
reversibility that is not dependent on the removal of exogenous
growth factors via culture media replacement, (v) provide lateral
inhibition, thereby reducing the random differentiation of
neighbouring cells and (vi) enable trigger-programmable and
(vii) precise differential transcription factor expression switches.
The synthetic lineage-control network that precisely replicates
the endogenous relative expression dynamics of the transcription
factors Pdx-1, Ngn3 and MafA required the design of a new
network topology that interconnects a synthetic signalling
cascade and a gene switch with differential and opposing
sensitivity to the food additive vanillic acid. This differentiation
device provides different band-pass ﬁlter, time-delay and feed-
forward ampliﬁer topologies that interface with endogenous
positive-feedback loops to orchestrate the timely expression and
repression of heterologous and chromosomally encoded Ngn3,
Pdx1 and MafA variants. The temporary nature of the
engineering intervention, which consists of transient transfection
of the genetic lineage-control components in the absence of any
selection, is expected to avoid stable modiﬁcation of host
chromosomes and alleviate potential safety concerns. In addition,
the resulting beta-cell mass could be encapsulated inside
vascularized microcontainers28, a proven containment strategy
in prototypic cell-based therapies currently being tested in animal
models of prominent human diseases14–16,61,62 as well as in
human clinical trials28.
The hIPSC-derived beta-like cells resulting from this trigger-
induced synthetic lineage-control network exhibited glucose-
stimulated insulin-release dynamics and capacity matching
the human physiological range and transcriptional proﬁling,
ﬂow cytometric analysis and electron microscopy corroborated
the lineage-controlled stem cells reached a mature beta-cell
phenotype. In principle, the combination of hIPSCs derived from
the adipose tissue of a 50-year-old donor59 with a synthetic
lineage-control network programming glucose-sensitive
insulin-secreting beta-like cells closes the design cycle of
regenerative medicine63. However, hIPSCs that are derived
from T1DM patients, differentiated into beta-like cells and
transplanted back into the donor would still be targeted by the
immune system, as demonstrated in the transplantation of
segmental pancreatic grafts from identical twins64. Therefore,
any beta-cell-replacement therapy will require complementary
modulation of the immune system either via drugs30,65,
engineering or cell-based approaches66,67 or packaging inside
vascularizing, semi-permeable immunoprotective microcontainers28.
Capitalizing on the design principles of synthetic biology, we
have successfully constructed and validated a synthetic lineage-
control network that replicates the differential expression
dynamics of critical transcription factors and mimicks the native
differentiation pathway to programme hIPSC-derived pancreatic
progenitor cells into glucose-sensitive insulin-secreting beta-like
Figure 4 | Gene expression proﬁling of beta-like cells programmed by the synthetic lineage-control network. Quantitative RT–PCR-based expression
proﬁling of the following genes in glucose-sensitive insulin-secreting beta-like cells differentiated by the lineage-control network: (a) the key pancreatic
beta-cell-speciﬁc transcription factors Glis3, MafA, MafB, Mnx1, NeuroD, Pax4, Pdx1 and Nkx6.1, (b) the glucose- and insulin-processing factors Gck, Glut2,
G6pc2, Pcsk1, Pcsk2, Slc30a8, Snap25, Stx1A, Stxbp1, Syt4, (c) the channels essential for the secretion of insulin such as Abcc8, Cacna1D, Kcnk1/3 and Kcnj11
and (d) the human islet peptide hormones Chgb, Ghrelin, Glucagon, Iapp, Insulin and Somatostatin, and (e) immature as well as mature human pancreatic
beta-cell markers Acox2, Ck19, Dpp4, FoxA1, Fzd2, Gcgr, Irx2, Mmp2, Onecut2, Sftpd and Ucn3. The transcript levels were proﬁled at day 11 relative to hIPSCs
and normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Data are the means±s.d. of triplicate experiments (n¼ 9). Abcc8, ATP-binding
cassette transporter sub-family C member 8; Acox2, Acyl-CoA oxidase 2; Cacna1D, voltage-dependent, L-type alpha 1D subunit; Chgb, chromogranin B;
Ck19, cytokeratin-19; Dpp4, dipeptidyl-peptidase 4; FoxA1, forkhead box protein A1; Fzd2, frizzled 2; Gcgr, glucagon receptor; Gck, glucokinase; Glis3, glis
family zinc ﬁnger 3; Glut2, glucose transporter 2; G6pc2, glucose-6-phosphatase 2; Iapp, islet amyloid polypeptide; Irx2, iroquois homeobox 2; Kcnk1/3,
potassium channel, subfamily K, member 1/3; Kcnj11, potassium inwardly-rectifying channel, subfamily J, member 11; MafA/B, V-maf musculoaponeurotic
ﬁbrosarcoma oncogene homologue A/B; Mmp2, matrix metalloproteinase 2; Mnx1, motor neuron and pancreas homeobox 1; NeuroD1, neurogenic
differentiation factor 1; Nkx6.1, NK6 homeobox 1; Onecut2, onecut homeobox 2; Pax4, paired box gene 4; Pcsk1/2, proprotein convertase 1/2; Sftpd,
surfactant protein D; Pdx1, pancreatic and duodenal homeobox 1; Slc30a8, solute carrier family 30, member 8; Snap25, synaptosomal-associated protein;
Stx1A (Syntaxin-1A), Stxbp1, syntaxin binding protein 1; Syt4 synaptotagmin-4; Ucn3, urocortin 3.
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cells that compare with human pancreatic islets at a high level.
The design of input-triggered synthetic lineage-control networks
that execute a preprogrammed sequential differentiation agenda
coordinating the timely induction and repression of multiple
genes could provide a new impetus for the advancement of
developmental biology and regenerative medicine.
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Figure 5 | Characterization of glucose-sensitive insulin-secreting beta-like cells programmed by the synthetic lineage-control network.
(a) Quantitative analysis of lineage-controlled beta-like cells co-stained for VanA1 and either insulin (C-peptide), glucagon or somatostatin. The cells
staining positive for VanA1 are containing the lineage-control network. Data are the means±s.d. (n¼ 3). (b,c) Human pancreatic islets and beta-like cells
produced by programming hIPSC-derived pancreatic progenitor cells using the synthetic lineage-control network or the growth-factor/chemical-based
differentiation technique were exposed to low (2.8mM), medium (10mM), high (20mM) glucose as well as high glucose and potassium chloride (30mM)
before intracellular (b) and secreted (c) insulin (C-peptide) levels were proﬁled using ELISA. Data are the means±s.d. of duplicate experiments (n¼6).
Statistics by Student’s t-test; *Po0.05, **Po0.005, ****Po0.0001; ns, not signiﬁcant. (d) Beta-like cells produced by programming hIPSC-derived
pancreatic progenitor cells using the synthetic lineage-control network or the growth-factor/chemical-based differentiation technique and cultivated for 4
weeks were exposed to low (2.8mM), medium (10mM), high (20mM) glucose as well as high glucose and potassium chloride (30mM) before secreted
insulin (C-peptide) levels were proﬁled using ELISA. Data are the means±s.d. of duplicate experiments (n¼ 6). Statistics by Student’s t-test; **Po0.005;
ns, not signiﬁcant. (e) Transmission-electron micrographs of human pancreatic islets and lineage-controlled beta-like cells. Scale bars, 1 mm (human
pancreatic islets) and 2 mm (beta-like cells differentiated by the synthetic lineage-control network).
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Methods
Network components. Comprehensive design and construction details for all
expression vectors are provided in Supplementary Table 1. Key plasmids are as
follows: pCI-MOR9-1 encodes constitutively expressed vanillic acid receptor
(MOR9-1; PhCMV-MOR9-1-pASV40); pSP1 encodes cAMP-responsive expression
cassette for the vanillic acid-dependent transactivator (VanA1; PCRE-VanA1-pASV40);
pSP12 contains a vanillic acid-responsive Ngn3cm, mFT and miR30Pdx1g-shRNA
expression unit (pASV40’Ngn3cm-P3VanO2-mFT-miR30Pdx1g-shRNA-pASV40) and
pSP17 contains a cAMP-responsive dicistronic Pdx1cm and MafAcm expression unit
(PCREm-Pdx1cm-2A-MafAcm-pASV40).
Cell culture and transfection. Human mesenchymal stem cells transgenic for the
catalytic subunit of human telomerase (hMSC-TERT68) were cultivated in DMEM
(Invitrogen) supplemented with 10% (vol/vol) fetal calf serum (FCS; lot no.
PE01026P, Bioconcept) and 1% (vol/vol) penicillin/streptomycin solution
(Sigma-Aldrich) at 37 C in a humidiﬁed atmosphere containing 5% CO2. The
hIPSCs were derived from the adipose tissue of a 50-year-old donor59. The hIPSCs
were cultivated in Geltrex-coated 12-well culture plates (Invitrogen) containing
1ml mTeSR1 medium (STEMCELL Technologies). For serial passage, the colonies
were enzymatically dissociated into cellular clumps (200–400 cells per clump) using
1Uml 1 dispase (STEMCELL Technologies). For the transfection of hMSC-
TERT, 2 105 cells were seeded per well on a six-well plate 12 h before transfection
and incubated for 24 h with 400 ml of a DNA-polyethyleneimine (PEI) mixture that
was produced by incubating 6 ml PEI (PEI, o20,000MW, Polysciences; stock
solution: 1mgml 1 ddH2O, pH 7.2) with 2 mg of total DNA, vortexing for 5 s and
incubating for 15min at 22 C. Before transfection, the hIPSCs-derived pancreatic
progenitor cells were dissociated using 0.5ml of StemPro Accutase Cell
Dissociation Reagent (Invitrogen) and reseeded into 12-well plates. For the
transfection, 3 mg of total DNA was transfected into cells cultivated in each well of a
12-well plate using Lipofectamine LTX Reagent with PLUS Reagent (Invitrogen).
The plasmids (pCI-MOR9-1; pSP1; pSP12; pSP17) were co-transfected at a ratio
of 1:1:1:1 for hIPSCs (1:0.01:1:1 for hMSC-TERT). The transfection efﬁciency was
determined via FACS analysis using pEGFP-N1-transfected, randomly
differentiating cells as a control (Supplementary Fig. 10). Randomly differentiating
or lineage-controlled hIPSC-derived pancreatic progenitor cell populations (day
11) were prepared for transfection by dissociating the cells with 0.5ml of StemPro
Accutase Cell Dissociation Reagent (Invitrogen), seeded into the wells of a 12-well
plate and cultivated for 4 h in 1ml RPMI (Invitrogen) containing 10% FCS and
supplemented with 10mM Y-27632, 11mM glucose, 400 mM vanillic acid
(Sigma-Aldrich), 50 ngml 1 exendin-4 (Tocris Bioscience), 10mM nicotinamide
(Sigma-Aldrich) and 40 mM b-mercaptoethanol. Subsequently, the culture medium
was replaced by the same supplemented RPMI devoid of Y-27632 and the cells
were transfected with 3 mg pSP26 (PhINS-DsRed-Express-pASV40) using
Lipofectamine LTX with Plus Reagent (Invitrogen). For FACS-mediated single-cell
sorting of the lineage- and growth-factor/chemical-controlled beta-like cells
(day 11), hIPSC-derived pancreatic progenitor cells (day 0) were co-transfected with
3mg of total DNA (pCI-MOR9-1, pSP1, pSP12, pSP17, pEGFP-N1, pSP26; for the
lineage-control network; pEGFP-N1, pSP26 for the growth-factor/chemical-based
differentiation technique). The parental vector pcDNA3.1(þ ) was used as a ﬁller
plasmid when replacing functional components for control purposes. For the
dose–response experiments, the transfected cells were trypsinized (200 ml trypsin,
5min, 37 C; PAN Biotech) and transferred into the wells of a 96-well plate
(104 cells per well) containing 100 ml DMEM supplemented with different
concentrations of vanillic acid. SEAP expression was proﬁled after 48 h. To
compare vanillic acid-triggered lineage control with independent expression
control of the pancreatic transcription factors Ngn3, Pdx1, MafA by different
antibiotic-responsive gene switches, we co-transfected hMSC-TERT with
pCI-MOR9-1, pSP1, pSP12 and pSP17 for the lineage-control network, with
pWW35, pSP36, pMF156 and pSP39 for macrolide-responsive Pdx1 and MafA
(EOFF) as well as streptogramin-responsive Ngn3 expression (PIPOFF) or with
pWW35, pSP37, pMF156, pSP39, pTet-ON and pSP4 for macrolide-responsive
Pdx1 (EOFF), streptogramin-responsive Ngn3 (PIPOFF) and tetracycline-responsive
MafA (TETON) expression, and incubated the cells in the presence of vanillic acid
(2mM medium concentration, 400 mM high concentration), erythromycin (1 mM;
Sigma-Aldrich), doxycycline (1 mM; Sigma-Aldrich) or pristinamycin (Pyostacin,
1 mM; Sanoﬁ-Aventis Inc.).
Differentiation of hIPSCs. The hIPSCs were differentiated to pancreatic
progenitor cells and beta-like cells using the growth-factor/chemical-based
differentiation techniques described below32–34,55,60. Step 1 (endoderm cells):
Human pluripotent stem cells (80–90% conﬂuence) were washed with 1 PBS
and cultivated for 24 h in RPMI containing Activin A (100 ngml 1) and Wnt3A
(25 ngml 1). Then, the cells were cultivated for another 48 h in RPMI containing
Activin A (100 ngml 1), bFGF (5 ngml 1), BMP-4 (0.25 ngml 1) and VEGF165
(10 ngml 1). Subsequently, the cells were cultivated for another 48 h in serum-free
differentiation (SFD) medium (75% Iscove’s modiﬁed Dulbecco’s medium,
25% Ham’s F-12, 0.5 N2 supplement, 0.5 vitamin A-free B 27
serum-free supplement, 0.1% bovine serum albumin, ascorbic acid (50 mgml 1),
1-thioglycerol (0.45 mM)) containing Activin A (100 ngml 1), bFGF (5 ngml 1),
BMP-4 (0.25 ngml 1) and VEGF165 (10 ngml 1). Step 2 (primitive gut tube
cells): The endoderm cells resulting from step 1 were cultivated for 72 h in SFD
medium containing Wnt3A (3 ngml 1), Noggin (50 ngml 1) and FGF-10
(50 ngml 1). Step 3 (pancreatic progenitor cells): The primitive gut tube cells
resulting from step 2 were cultivated for 72 h in DMEM containing 1% (vol/vol)
vitamin A-free B 27 serum-free supplement, ascorbic acid (50 mgml 1),
KAAD-cyclopamine (0.25 mM), retinoic acid (2mM) and FGF-10 (50 ngml 1).
Step 4 (pancreatic progenitor cells): The pancreatic progenitor cells resulting from
step 3 were cultivated for 72 h in DMEM containing 1% (vol/vol) vitamin A-free
B 27 serum-free supplement, ascorbic acid (50 mgml 1), retinoic acid (100 nM),
FGF-7 (50 ngml 1) and epidermal growth factor (EGF; 50 ngml 1). Step 5
(endocrine progenitor cells): The pancreatic progenitor cells resulting from step 4
were treated for 4 h with Y-27632 (10 mM), dissociated for 5min using 0.5ml of
StemPro Accutase and incubated for 72 h in suspension plates to facilitate the
formation of aggregates in DMEM containing 1% (vol/vol) vitamin A-free B 27
serum-free supplement, ascorbic acid (50 mgml 1), retinoic acid (50 nM),
thyroid hormone T3 (1mM), Alk5 inhibitor (10 mM), Noggin (50 ngml 1),
KAAD-cyclopamine (0.25 mM) and gamma secretase inhibitor (1 mM). Step 6
(maturing beta-like cells): The endocrine progenitor cells resulting from step 5
were cultivated for 72 h in DMEM containing 1% (vol/vol) vitamin A-free B 27
serum-free supplement, ascorbic acid (50mgml 1), retinoic acid (25 nM), thyroid
hormone T3 (1 mM), Noggin (50 ngml 1), Alk5 inhibitor (10 mM) and gamma
secretase inhibitor (1 mM). Step 7 (beta-like cells): The maturing beta-like cells
resulting from step 6 were cultivated for 5 days in low-glucose DMEM (5mM
glucose) supplemented with 10% (vol/vol) FCS and containing 1 non-essential
amino acid solution, thyroid hormone T3 (1 mM) and Alk5 inhibitor (10 mM). For
the lineage-control network, 12-well suspension plates (Greiner Bio-one GmbH.)
were used from day 0 onwards and hIPSC-derived endodermal cells were cultivated
in noggin- and gamma-secretase inhibitor-free culture medium (to prevent
premature endocrine differentiation before transfection of the lineage-control
network) supplemented with epidermal growth factor (to trigger expression of
Nkx6.1 in pancreatic progenitor cells). After dissociation and transfection of the
pancreatic progenitor cells with the lineage-control network, the engineered cells
spontaneously form aggregates and following addition of thyroid hormone T3
(triiodothyronine) and retinoic acid they differentiate into endocrine progenitor
cells and mature into beta-like cells following addition of Alk5 inhibitor
(Supplementary Fig. 1). Randomly differentiating pancreatic progenitor cells were
cultivated in DMEM supplemented with 10% (vol/vol) KnockOut Serum
Replacement (KOSR) for 4 days and then for 7 days in SFD supplemented with
10% (vol/vol) KOSR. Roswell Park Memorial Institute (RPMI) 1640 culture
medium, Iscove’s modiﬁed Dulbecco’s medium, Ham’s F12 nutrient mixture,
Vitamin A-free B 27 serum-free supplement, N-2 supplement, human bFGF,
KOSR, non-essential amino-acid solution, PBS and StemPro Accutase cell
dissociation reagent were purchased from Invitrogen. Human BMP4, the sonic
hedgehog antagonist KAAD-Cyclopamine, human Noggin, human EGF, human
ﬁbroblast growth factor 7/10 (FGF-7/FGF-10) and human VEGF165 were obtained
from Miltenyi Biotec. Human Activin A, wingless-type MMTV integration site
family member 3A (Wnt3A), vanillic acid, ascorbic acid, bovine serum albumin,
1-thioglycerol, thyroid hormone T3 and retinoic acid were purchased from
Sigma-Aldrich. The gamma secretase inhibitor L-685,458 was obtained from Tocris
Bioscience, Rock inhibitor Y-27632 was obtained from STEMCELL Technologies
and Alk5 inhibitor was obtained from Enzo Lifesciences.
Immunocytochemistry. At different time points of the differentiation (endoderm
cells; pancreatic progenitor cells, endocrine progenitor cells; pancreatic beta-like
cells; Supplementary Fig. 1), network-containing hIPSCs cultivated in 12-well
plates were ﬁxed with 4% (wt/vol) paraformaldehyde solution overnight at 4 C.
The ﬁxed cells were permeabilized with 0.1% (vol/vol) Triton X-100 solution and
then incubated with blocking solution (10% (vol/vol) goat serum in PBS) for 1 h at
37 C followed by 40 ,6-diamidino-2-phenylindole-mediated staining of the cell
nuclei (Vectashield; Vector Labs). The samples were immunostained for 1 h at
37 C using primary antibodies speciﬁc for Sox17 and Fox A2 (endoderm cells),
Pdx1, Nkx6-1 (pancreatic progenitor cells), Ngn3, Pdx1 and VP16 (endocrine
progenitor cells) and insulin (C-peptide), VP16, Pdx1, MafA, glucagon and
somatostatin (pancreatic beta-like cells), washed three times in 0.1% Tween-20 and
incubated for 1 h with appropriate ﬂuorophore-conjugated secondary antibodies
before immunoﬂuorescence was visualized with a Nikon Eclipse Ti microscope
(Nikon AG) using the appropriate excitation/emission wavelengths. The primary
antibodies utilized in this study included mouse anti-Sox17 IgG (MAB19241, lot
no. C614013; dilution 1:1,000; R&D Systems Europe), rabbit anti-FoxA2 IgG
(AB4125, lot no. NMM1757191; dilution 1:1,000; Millipore), rabbit anti-VP16 IgG
(ab4808, lot no. 830675; dilution 1:200; Abcam), mouse anti-Ngn3 IgG (F25A1B3,
lot no. GR95038; dilution 1:100; Developmental Studies Hybridoma Bank), mouse
anti-Pdx1 IgG (MAB2419, lot no. C267712; dilution 1:2,000; R&D Systems), rabbit
anti-MafA IgG (sc-66958, lot no. C1609; dilution 1:100; Santa Cruz Biotechnology),
rat anti-C-peptide IgG (GN-ID4, lot no. 10510; dilution 1:50; Developmental
Studies Hybridoma Bank), goat anti-glucagon IgG (sc-7779, lot no. E2112; dilution
1:200; Santa Cruz Biotechnology), mouse anti-somatostatin IgG (sc-74556, lot
no. J2708; dilution 1:200; Santa Cruz Biotechnology) and rat anti-Nkx6-1 IgG
(F55A12-s, dilution 1:200; Developmental Studies Hybridoma Bank). The
secondary antibodies utilized in this study included ﬂuorescein (FITC)-conjugated
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goat anti-mouse IgG (AP124F, lot no. LV1688510; dilution 1:1,000), rhodamine-
conjugated goat anti-rabbit IgG (AP307R, lot no. LV1441875; dilution 1:1,000)
from Millipore Inc, donkey anti-goat IgG (sc-3860, lot no. G1712; dilution 1:400)
and ﬂuorescein (FITC)-conjugated chicken anti-rat IgG (sc-2991, lot no. K2912;
dilution 1:400) from Santa Cruz Biotechnology.
Analytical assays. The production of human placental SEAP was quantiﬁed in
cell culture supernatants using a p-nitrophenylphosphate-based light absorbance
time course69. Activity of Gaussia princeps Luciferase was quantiﬁed using a
BioLux Gaussia Luciferase Assay Kit (New England Biolabs Inc.). The activity of
Photinus pyralis ﬁreﬂy luciferase (FLuc) was quantiﬁed using a Luciferase Assay
System (Promega).
Quantitative RT–PCR. Total RNA of lineage-controlled hIPSC population,
FACS-sorted hIPSC-derived beta-like cells, engineered hMSC-TERT and human
islets was isolated using the ZR RNA MiniPrep kit (Zymo Research) and TURBO
DNase (Invitrogen). qRT–PCR with total RNA was performed using SuperScript II
Reverse Transcriptase (Invitrogen) and TaqMan Fast Advanced Mastermix
(Invitrogen) with the corresponding TaqMan Gene Expression Assays
(Supplementary Table 2) or SYBR Green PCR Mastermix with custom-designed
primers (Supplementary Table 3). qRT–PCR with total RNA of FACS-sorted
hIPSC-derived beta-like cells and human islets was performed using High-Capacity
cDNA Reverse Transcription Kit (Invitrogen) and Taqman PreAmp Mastermix
Kit (Invitrogen) with the corresponding TaqMan Gene Expression Assays
(Supplementary Table 2). The Eppendorf Realplex Mastercycler (Eppendorf
GmbH) was set to the following ampliﬁcation parameters: 2min at 50 C, 20 s
at 95 C and 40 cycles of 1 s at 95 C followed by 1min at 60 C. The relative
threshold cycle (Ct) was determined and normalized to the endogenous
glyceraldehyde 3-phosphate dehydrogenase transcript. The fold change for each
transcript relative to the control was calculated using the comparative Ct method70.
FACS-mediated analysis and single-cell sorting. For FACS-mediated analysis
and single-cell sorting of randomly differentiating and lineage-controlled hIPSC-
derived beta-like cells (day 11), the cell populations was co-transfected with pSP26
(PhINS-DsRed-Express-pASV40) and the resulting beta-like cells were sorted (day
14) using a Becton Dickinson LSRII Fortessa ﬂow cytometer (Becton Dickinson)
equipped for DsRed (561 nm laser, 570 nm long-pass ﬁlter, 586/15 emission ﬁlter)
detection. For FACS-mediated analysis and single-cell sorting of hIPSC-derived
beta-like cells differentiated using the growth-factor/chemical-based differentiation
technique (day 11), the respective treated population (day 0) was co-transfected
with 3 mg of total DNA (pCI-MOR9-1, pSP1, pSP12, pSP17, pEGFP-N1,
pSP26) for the lineage-control network; (pEGFP-N1, pSP26) for the growth-fac-
tor/chemical-based differentiation technique and the resulting beta-like cells were
sorted using DsRed (561 nm laser, 570 nm long-pass ﬁlter, 586/15 emission ﬁlter)
detection and EGFP (488 nm laser, 505 nm long-pass ﬁlter, 530/30 emission ﬁlter)
detection while excluding dead cells and cell doublets. Total RNA extracted from
the sorted beta-like cells was used for qRT–PCR. For FACS analysis, we used the
same antibodies and dilutions as for immunostaining. In brief, cells were detached
(1 106 cells per ml) using 0.5ml StemPro Accutase Cell Dissociation Reagent
(Invitrogen) and ﬁxed with 4% (wt/vol) paraformaldehyde in PBS overnight at
4 C, permeabilized for 10min with 0.1% (vol/vol) Triton X-100, washed once in
2ml PBS and sequentially labelled for 1 h at 37 C with speciﬁc primary and
secondary antibodies, with a PBS washing step in between. The cell populations
were analysed using a Becton Dickinson LSRII Fortessa ﬂow cytometer (Becton
Dickinson) equipped for EGFP (488 nm laser, 505 nm long-pass ﬁlter, 530/30
emission ﬁlter), DsRed (561 nm laser, 570 nm long-pass ﬁlter, 586/15 emission
ﬁlter) or allophycocyanin (ACP, 633 nM laser, 670/14 emission ﬁlter) detection and
set to exclude dead cells and cell doublets. Unstained cell populations were used as
negative controls.
Transmission electron microscopy. Human islets and beta-like cells differ-
entiated using the lineage-control network (day 11) were dissociated into single
cells using 0.5ml of StemPro Accutase Cell Dissociation Reagent (Invitrogen) and
prepared for electron-microscopic analysis using a standard procedure34. In brief,
after embedding the cell pellets in EMbed 812 resin (Electron Microscopy
Sciences), serial 70 nm sections were collected on formvar-coated copper slot grids
(Electron Microscopy Sciences) and micrographs were taken using a FEI/Philips
CM-10 transmission electron microscope (FEI/Philips) equipped with a 2k 2k
CCD Veleta camera (EMSIS, GmbH).
Quantiﬁcation of glucose responsiveness. Human islets and beta-like cells
either differentiated by the synthetic lineage-control network or using the growth-
factor/chemical-based differentiation technique (day 11) were washed in 0.25ml
Krebs-Ringer Bicarbonate Buffer (129mM NaCl, 5mM NaHCO3, 4.8mM KCl,
1.2mM KH2PO4, 1.2mM MgSO4, 2.5mM CaCl2, 10mM HEPES, pH 7.4; Sigma-
Aldrich) and incubated for 30min in low-glucose (Sigma-Aldrich; 2.8mM) Krebs-
Ringer Bicarbonate Buffer supplemented with 100mM 3-isobutyl-1-methylxanthine
(Sigma-Aldrich). The culture was then switched to intermediate glucose (10mM)
for 30min and then high-glucose (20mM) Krebs-Ringer Bicarbonate Buffer for
another 30min. Thereafter, the culture was switched to high-glucose (20mM) and
KCl (30mM)-supplemented Krebs-Ringer Bicarbonate Buffer for another 30min.
The intracellular (released via cell lysis for 5min at 22 C in M-PER protein lysis
buffer; Thermo Scientiﬁc) and secreted isoforms of the connecting peptide
(C-peptide) produced during proinsulin processing were quantiﬁed using the
ultrasensitive human C-peptide ELISA (lot no. 21899; Mercodia). The values
were normalized to the total intracellular protein content and the number of
glucose-sensitive insulin-secreting cells using a Bio-Rad protein assay (Bio-Rad
Laboratories). For the extended culture, beta-like cells (day 11) were continuously
cultivated for 4 weeks in DMEM (Invitrogen) containing 10% (vol/vol) FCS,
5mM glucose, 400 mM vanillic acid (Sigma-Aldrich), 1 mM thyroid hormone T3
(Sigma-Aldrich) and 10mM Alk5 inhibitor before glucose-stimulated insulin
release was quantiﬁed.
Statistical analyses. All data represent the means±s.d. of three independent
experiments with two or three samples per experiment. Group comparisons were
analysed by the Student’s t-test (cutoff of Po0.05) using GraphPad Prism 6
software (GraphPad Software Inc.).
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